Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of AN2728 2% topical ointment in atopic dermatitis (age ≥2 years)
2018-000904-40Phase 3
- Sponsor
- Pfizer
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of crisaborole in atopic dermatitis (AD), sponsored by Pfizer. Primary endpoint: Adverse events.
02
Drugs
crisaborole
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-000904-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000904-40.